颖泰生物
(920819)
| 流通市值：37.80亿 | | | 总市值：38.24亿 |
| 流通股本：12.12亿 | | | 总股本：12.26亿 |
| 报告期 | 2026-03-31 | 2025-12-31 | 2025-09-30 | 2025-06-30 |
| 公司类型 | 通用 | 通用 | 通用 | 通用 |
| 一、营业总收入 | 1,355,490,197.14 | 5,474,030,024.74 | 4,265,739,103.06 | 2,859,791,830.89 |
| 营业收入 | 1,355,490,197.14 | 5,474,030,024.74 | 4,265,739,103.06 | 2,859,791,830.89 |
| 二、营业总成本 | 1,364,489,867.01 | 5,533,691,285.33 | 4,280,746,863.52 | 2,865,648,174.8 |
| 营业成本 | 1,193,946,686.53 | 4,779,455,867.49 | 3,716,613,243.61 | 2,499,920,320.8 |
| 税金及附加 | 9,594,278.28 | 33,040,783.03 | 26,134,401.61 | 15,971,918.65 |
| 销售费用 | 20,110,579.05 | 92,317,723.24 | 66,451,537.7 | 44,813,768.83 |
| 管理费用 | 67,586,940.44 | 326,790,788.65 | 236,624,105.8 | 156,054,675.12 |
| 研发费用 | 21,101,892.91 | 130,383,752.5 | 118,079,806.27 | 78,896,388.6 |
| 财务费用 | 52,149,489.8 | 171,702,370.42 | 116,843,768.53 | 69,991,102.8 |
| 其中:利息费用 | 37,861,153.25 | 171,796,168.67 | 121,582,410.54 | 81,531,049.94 |
| 其中:利息收入 | 2,365,208.42 | 17,229,582.46 | 12,584,320.13 | 8,660,485.32 |
| 三、其他经营收益 | | | | |
| 加:公允价值变动收益 | -3,127,642.63 | -1,370.4 | 725,584.92 | 1,178,100.54 |
| 加:投资收益 | 2,265,270.36 | -61,730,501.82 | -16,194,477.36 | 20,751,086.12 |
| 资产处置收益 | 2,369,926.58 | 13,433,851.23 | 16,550,638.59 | 11,784,053.1 |
| 资产减值损失(新) | -4,211,815.26 | -95,483,872.25 | -3,446,963.22 | -5,388,207.16 |
| 信用减值损失(新) | 2,709,956.52 | -34,472,398.05 | 2,296,345.97 | 571,265.78 |
| 其他收益 | 4,924,766.83 | 29,443,059.13 | 25,213,280.8 | 14,514,805.93 |
| 四、营业利润 | -4,069,207.47 | -208,472,492.75 | 10,136,649.24 | 37,554,760.4 |
| 加:营业外收入 | 2,262,452.12 | 4,040,898.01 | 3,124,727.02 | 1,042,631.02 |
| 减:营业外支出 | 2,190,556.08 | 11,131,214.41 | 5,204,182.65 | 3,674,252.56 |
| 五、利润总额 | -3,997,311.43 | -215,562,809.15 | 8,057,193.61 | 34,923,138.86 |
| 减:所得税费用 | 16,596,706.95 | 44,835,728.95 | 19,688,515.2 | 21,961,019.09 |
| 六、净利润 | -20,594,018.38 | -260,398,538.1 | -11,631,321.59 | 12,962,119.77 |
| (一)按经营持续性分类 | | | | |
| 持续经营净利润 | -20,594,018.38 | -260,398,538.1 | -11,631,321.59 | 12,962,119.77 |
| (二)按所有权归属分类 | | | | |
| 归属于母公司股东的净利润 | -19,746,738.88 | -256,943,685.05 | -9,626,574.46 | 15,290,875.02 |
| 少数股东损益 | -847,279.5 | -3,454,853.05 | -2,004,747.13 | -2,328,755.25 |
| 扣除非经常损益后的净利润 | -22,267,965.88 | -282,108,452.23 | -38,211,048.87 | 992,860.09 |
| 七、每股收益 | | | | |
| (一)基本每股收益 | -0.02 | -0.21 | -0.01 | - |
| (二)稀释每股收益 | -0.02 | -0.21 | -0.01 | - |
| 八、其他综合收益 | -13,752,449.56 | -3,197,989.92 | 24,928,584.13 | 35,291,850.54 |
| 归属于母公司股东的其他综合收益 | -13,752,449.56 | -3,197,989.92 | 24,928,584.13 | 35,291,850.54 |
| 九、综合收益总额 | -34,346,467.94 | -263,596,528.02 | 13,297,262.54 | 48,253,970.31 |
| 归属于母公司股东的综合收益总额 | -33,499,188.44 | -260,141,674.97 | 15,302,009.67 | 50,582,725.56 |
| 归属于少数股东的综合收益总额 | -847,279.5 | -3,454,853.05 | -2,004,747.13 | -2,328,755.25 |
| 公告日期 | 2026-04-24 | 2026-04-16 | 2025-10-24 | 2025-08-15 |
| 审计意见(境内) | | 标准无保留意见 | | |